Impact of ivermectin administered for scabies treatment on the prevalence of head lice in Atoifi, Solomon Islands

Publication Type:Journal Article
Year of Publication:2018
Authors:S. Coscione, Esau, T., Kekeubata, E., Diau, J., Asugeni, R., MacLaren, D., Steer, A. C., Kositz, C., Marks, M.
Journal:PLOS Neglected Tropical Diseases
Volume:12
Issue:9
Pagination:e0006825
Date Published:Sept 2018
Abstract:

Background
Scabies and head lice are ubiquitous ectoparasitic infestations that are common across the Pacific Islands. Ivermectin is an effective treatment for both conditions, although the doses used vary. At a community level, mass drug administration (MDA) with ivermectin is an effective strategy to decrease prevalence of scabies. To what extent MDA with ivermectin will also reduce prevalence of head lice is unknown.
Methodology
Head lice prevalence was assessed before and after MDA with oral ivermectin (at a dose of 200 micrograms per kilogram of body weight) administered on day 1 and day 8. The primary outcome was the change in prevalence of head louse infestation at two weeks compared to baseline. Longer term efficacy was assessed three months after MDA.
Results
118 participants were enrolled. Baseline prevalence of active head louse infestation was 25.4% (95% CI 18.4–34.0). At two-week follow-up, prevalence was 2.5% (95% CI 0.9–7.2), a relative reduction of 89.1% (95% CI 72.7–91.4%, p <0.001).At three-month follow-up, prevalence was 7.5% (95% CI 2.7–12.3), a relative reduction of 70.6% (95% CI 72.7%-91.4%, p <0.001). Head louse infestation was associated with younger age (age 􏰔10 years: prevalence 46.7%; adjusted odds ratio compared to adults of 7.2, 95%CI 2.0–25.9) and with having at least one other member of the household with active head louse infestation (adjusted odds ratio 4.3, 95%CI 1.7–11.1).
Conclusions
Head louse infestation is common in the Solomon Islands. This proof of principle study shows that oral ivermectin at a dose of 200 micrograms per kilogram can reduce the burden of active head louse infestation, offering an additional collateral benefit of MDA with ivermec- tin for scabies control.

Trial registration: ClinicalTrials.gov NCT03236168.

Author summary
Head lice and scabies are both caused by ectoparasites and lead to itchy skin conditions that are associated with secondary bacterial infections and social stigma. Both are com- mon in developing countries. In the Solomon Islands, mass treatment of communities using ivermectin (at dose of 200 micrograms per kilogram) has been shown to be an effec- tive strategy in reducing scabies prevalence. This study shows that the same dose of iver- mectin and the same regime of mass drug administration is also effective at reducing the burden of head louse infestation, offering an additional benefit to community wide treatment.

URL:https://dx.plos.org/10.1371/journal.pntd.0006825
DOI:10.1371/journal.pntd.0006825
Short Title:PLoS Negl Trop Dis
File attachments: 
Thu, 2019-10-03 11:58 -- Yokb
Scratchpads developed and conceived by (alphabetical): Ed Baker, Katherine Bouton Alice Heaton Dimitris Koureas, Laurence Livermore, Dave Roberts, Simon Rycroft, Ben Scott, Vince Smith